Metastases in bones, lymph nodes and lungs are common challenges among oncology patients (e.g. breast cancer, prostate cancer, osteosarcoma) and are the primary cause of death. Efficacious new treatment options are sorely needed. Alpha-particle emitting radionuclides being highly cytotoxic may fulfil this critical need. We study a novel technology with potentially broad therapeutic applications for cancer micrometastases by means of dual targeted alpha particle radiation. The treatment involves administration of a bone-seeking, alpha-particle emitting radionuclide 224Ra and its daughter radionuclide 212Pb solution containing chelator-labelled new and existing molecular ligands and tumour-associated monoclonal antibodies (mAb) as carriers for the daughter radionuclide. Pb-212 is a source of highly cytotoxic alpha particles via its decay to 212Bi daughter.
Contact information Asta Juzeniene, Scientist, Ph.D. Department of Radiation Biology, Institute for Cancer Research The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway Tel. +47 22 78 12 00, Fax +47 22 78 12 07
Li RG, Napoli E, Jorstad IS, Bønsdorff TB, Juzeniene A, Bruland ØS, Larsen RH, Westrøm S(2020) Calcium Carbonate Microparticles as Carriers of 224Ra: Impact of Specific Activity in Mice with Intraperitoneal Ovarian Cancer Curr Radiopharm(in press) DOI 10.2174/1874471013666201201102056, PubMed 33261548
Köksal H, Dillard P, Juzeniene A, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S(2020) Combinatorial CAR design improves target restriction J Biol Chem(in press) DOI 10.1074/jbc.RA120.016234, PubMed 33234592
Napoli E, Stenberg VY, Juzeniene A, Hjellum GE, Bruland ØS, Larsen RH(2020) Calibration of sodium iodide detectors and reentrant ionization chambers for 212Pb activity in different geometries by HPGe activity determined samples Appl Radiat Isot, 166, 109362 DOI 10.1016/j.apradiso.2020.109362, PubMed 32979756